18.04.2024 • News

Arkema Acquires Majority Stake in Proionic for Next-Gen Batteries

Arkema is set to acquire a 78% stake in Proionic, a start-up specializing in ionic liquids production. These components are crucial for future lithium-ion batteries. This acquisition expands Arkema’s solutions and strengthens its position in the materials sector across various battery technologies.

Proionic, a leading start-up in ionic liquids, was founded by Roland Kalb in 2004 in Graz, Austria. The company’s innovative technologies allow for the synthesis and recycling of these liquids, which are essential for next-gen solid and flexible batteries due to their electrical conductivity and non-flammability.

Armand Ajdari, Arkema's Chief Technology Officer commented, "With Proionic, Arkema continues to enrich its unique portfolio of differentiating technologies, and strengthens its position as the partner of choice for co-developing the safer, more efficient and more sustainable batteries of the future. We are delighted to welcome Proionic's teams to this great adventure."

Arkema’s acquisition of Proionic strengthens its position in the battery ecosystem and expands its high-performance materials portfolio. Ionic liquids, key to Proionic’s success, are used in biomass processing and metal treatment, aligning with Arkema’s sustainable solutions strategy. With €2.5 million sales in 2023, Proionic is expected to grow rapidly due to synergies with Arkema.

 

Company

Logo:

Arkema

420 rue d’Estienne d’Orves
92705 Colombes Cedex
France

Company contact







Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.